- Home
- ATOS vs GECC Comparison
ATOS vs GECC Comparison
Compare ATOS & GECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- GECC
- Stock Information
- Founded
- ATOS 2009
- GECC 2016
- Country
- ATOS United States
- GECC United States
- Employees
- ATOS N/A
- GECC N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- GECC Finance: Consumer Services
- Sector
- ATOS Health Care
- GECC Finance
- Exchange
- ATOS Nasdaq
- GECC Nasdaq
- Market Cap
- ATOS 107.2M
- GECC 127.9M
- IPO Year
- ATOS 2012
- GECC N/A
- Fundamental
- Price
- ATOS $0.84
- GECC $11.29
- Analyst Decision
- ATOS Strong Buy
- GECC Strong Buy
- Analyst Count
- ATOS 3
- GECC 1
- Target Price
- ATOS $6.17
- GECC $11.50
- AVG Volume (30 Days)
- ATOS 473.0K
- GECC 77.4K
- Earning Date
- ATOS 11-11-2025
- GECC 10-30-2025
- Dividend Yield
- ATOS N/A
- GECC 13.56%
- EPS Growth
- ATOS N/A
- GECC 29.91
- EPS
- ATOS N/A
- GECC 1.58
- Revenue
- ATOS N/A
- GECC $47,638,000.00
- Revenue This Year
- ATOS N/A
- GECC $28.14
- Revenue Next Year
- ATOS N/A
- GECC N/A
- P/E Ratio
- ATOS N/A
- GECC $7.12
- Revenue Growth
- ATOS N/A
- GECC 29.12
- 52 Week Low
- ATOS $0.55
- GECC $8.87
- 52 Week High
- ATOS $1.66
- GECC $11.39
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- GECC 61.97
- Support Level
- ATOS $0.81
- GECC $11.11
- Resistance Level
- ATOS $0.80
- GECC $11.32
- Average True Range (ATR)
- ATOS 0.03
- GECC 0.08
- MACD
- ATOS 0.01
- GECC -0.01
- Stochastic Oscillator
- ATOS 92.67
- GECC 69.81
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.